aTyr Pharma Announces LTBP1 as Target of DARS tRNA Synthetase Fragment
15. Dezember 2022 08:00 ET
|
aTyr Pharma, Inc.
LTBP1 is key regulator of TGF-β, a major driver of fibrosis. Latest target identified from company’s platform in collaboration with Dualsystems Biotech AG. SAN DIEGO, Dec. 15, 2022 (GLOBE...
aTyr Pharma to Present at the Jefferies London Healthcare Conference
25. Oktober 2022 08:00 ET
|
aTyr Pharma, Inc.
SAN DIEGO, Oct. 25, 2022 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of first-in-class medicines from its proprietary...
aTyr Pharma Announces Research Collaboration with Dualsystems Biotech AG to Identify 10 New Therapeutic Targets
11. Oktober 2022 08:00 ET
|
aTyr Pharma, Inc.
SAN DIEGO, Oct. 11, 2022 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE) (aTyr or “the Company”), a biotherapeutics company engaged in the discovery and development of first-in-class medicines...
aTyr Pharma to Present at the H.C. Wainwright 24th Annual Global Investment Conference 2022
06. September 2022 08:00 ET
|
aTyr Pharma, Inc.
SAN DIEGO , Sept. 06, 2022 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of first-in-class medicines from its proprietary...
aTyr Pharma to Present Poster at the European Respiratory Society (ERS) International Congress 2022
01. September 2022 08:00 ET
|
aTyr Pharma, Inc.
SAN DIEGO, Sept. 01, 2022 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of first-in-class medicines from its proprietary...
aTyr Pharma to Webcast Conference Call Reporting Second Quarter 2022 Financial Results
04. August 2022 08:00 ET
|
aTyr Pharma, Inc.
SAN DIEGO, Aug. 04, 2022 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of first-in-class medicines from its proprietary...
aTyr Pharma Announces New tRNA Synthetase Discovery Programs
11. Februar 2021 08:00 ET
|
aTyr Pharma, Inc.
Advancement of selected AARS and DARS fragments primarily targeting cancer Programs will accelerate discoveries initially focusing on natural killer (NK) cell biology SAN DIEGO , Feb. 11, 2021 ...
aTyr Pharma to Present at Jefferies 2018 Global Healthcare Conference
31. Mai 2018 08:00 ET
|
aTyr Pharma, Inc.
SAN DIEGO, May 31, 2018 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq:LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel immunological...
aTyr Pharma to Host Conference Call and Webcast of Full Year 2017 Financial Results on March 19, 2018
07. März 2018 08:00 ET
|
aTyr Pharma, Inc.
SAN DIEGO, March 07, 2018 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq:LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel immunological...
aTyr Pharma to Present at Two Upcoming Investor Conferences in March
01. März 2018 08:00 ET
|
aTyr Pharma, Inc.
SAN DIEGO, March 01, 2018 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq:LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel immunological...